Definium Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1 World Trade Ctr Ste 8500, New York, Ne...Phone Number
(212) 220-6633Website
www.definiumtx.comRevenue
-Stock Symbol
DFTXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Definium Therapeutics
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.Explore more
Definium Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Definium Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Definium Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Definium Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Definium Therapeutics
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Definium Therapeutics has new funding data
Earning: See what the market has to say on Definium Therapeutics recently announced quarterly report
Click to see if Definium Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Definium Therapeutics launches new products
Check out if Definium Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Definium Therapeutics
Find 2 more new buyers
Definium Therapeutics financials insights
Gather financial insights about Definium Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Stock/Share Issuance
$700M
Definium Therapeutics Tech Stack
A closer look at the technologies used by Definium Therapeutics
See more technologies
Most Recent Scoops
Project
Definium Therapeutics has reported that at week 6 of the Emerge Phase 3 study of DT120 ODT, 24% of treated participants achieved remission (MADRS score of 12 or below) versus 3% in the placebo group, 41% of treated participants reached mild or better status versus 13% in the placebo group, and 35% of treated participants achieved a response (greater than 50% reduction in score) versus 7% in the placebo group, with each measure reaching high statistical significance.
Clinical Operations
Funding
Funding
Project
Definium Therapeutics is advancing MM-120, an orally dissolving tablet (ODT) formulation of LSD being developed for generalized anxiety disorder (GAD) and major depressive disorder (MDD), with a breakthrough therapy designation secured for the GAD program.
Pharmaceuticals
Project
disclosed that sample size re-estimations for its Phase III GAD studies showed dropout rates reduced from 25% observed in Phase II to 10% and 6% in the two respective GAD studies, attributing the improvement to the design of the extension phase.
Clinical Operations
Hiring Plans
Hiring Plans
Definium Therapeutics News & Media
Definium Therapeutics (DFTX) Lands Phase 3 Win And Raises $700 Million For DT120
Definium Therapeutics (NasdaqGS:DFTX) reported positive topline Phase 3 results for DT120 in major depressive disorder. The company completed a US$700 million follow on equity offering to fund regulatory and commercialization plans for DT120. The latest data readout and capital raise were announced together as Definium Therapeutics positions DT120 for potential market entry. Definium Therapeutics focuses on treatments for psychiatric conditions, with DT120 targeting major depressive...Robert Barrow Chief Executive Officer at Definium Therapeutics
Rob has served as CEO since June 2021, transforming the company into a leading psychedelic medicine biotech focused on advancing psychiatry.Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028
Definium Therapeutics Inc (NASDAQ:DFTX) is among the best psychedelic stocks to buy in 2026. The company’s flagship drug candidate, DT120, is undergoing Phase 3 trials for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), and other psychiatric conditions. Its other drug candidate, DT402, targets autism spectrum disorder and is undergoing Phase 2 […]
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Definium Therapeutics
Sign Up For FreeTo access detailed company insights
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methyl... Read More
